Firebrick Pharma Limited (AU:FRE) has released an update.
Firebrick Pharma Limited has announced the filing and successful validation of their Marketing Authorisation Application in Europe for Nasodine, a nasal antiseptic spray. The application is currently under evaluation, with an initial decision expected by 19 December 2024. If approved, the company plans to partner with European entities for manufacturing, distribution, and marketing.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.
